- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07640087
Effects Of Physical Training On Cardiovascular Capacity In Patients Undergoing Chemotherapy For Cancer (Cancer)
Introduction: Cancer treatment, especially chemotherapy and radiotherapy, can lead to cardiovascular dysfunctions, such as a decrease in left ventricular ejection fraction and electrical dysfunction of the heart, which may consequently compromise patients' quality of life. In this context, physical exercise is a beneficial and promising tool, as it can prevent and minimize the deleterious effects of oncological therapies and their complications.
Objective: To evaluate the effect of physical exercise on the prevention of cardiovascular diseases (CVD) induced by cancer treatment, analyzing the impact of supervised exercise on cardiovascular function and quality of life.
Materials and Methods: This is a clinical trial in which the sample will consist of 60 individuals undergoing cancer treatment, who will be stratified and randomized according to cancer stage classification into two groups: Intervention Group (IG) and Control Group (CG). The intervention will last 12 weeks, during which the IG will receive a prescription for physical exercises based on the FITT principle (frequency, intensity, time, and type), three times per week, while the CG will remain under usual care. Data will be presented using descriptive statistics, tests for two independent samples, and multivariate analysis, comparing the intervention effects between the two groups using R software version 4.3.3.
Expected Results: Low incidence of CVD, improved heart rate variability, adherence to the exercise protocol, reduced risk for cardiovascular diseases, improvement in fatigue, functional capacity, and quality of life. Data will be collected at baseline, at the 6th week, and at the 12th week of intervention.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Cancer is a disease characterized by the uncontrolled growth of abnormal cells that invade organs and tissues. It is one of the leading causes of mortality worldwide, with high incidence and prevalence. Despite the progress in cancer treatment, it can generate a range of side effects and increase the risk of developing other diseases.
Cardio-oncology has become an area of great importance in research and presents a bidirectional relationship, as it links cardiovascular diseases to the risk of developing cancer and vice versa. It also focuses on the early diagnosis of CVD in patients undergoing cancer treatment. Cardio-oncology investigates and identifies factors that may cause cardiac damage, compromising the heart's structure and function, and relates these factors to the chemotherapy used.
One of the complications of chemotherapy is anthracycline-induced cardiotoxicity, which leads to increased expression of cellular senescence and adverse effects on the heart, including ventricular dysfunction, arrhythmias, myocardial fibrosis, and heart failure. These effects are dose-dependent and may be irreversible.
In this context, it is essential to adopt strategies that mitigate the impact of cardiotoxicity, improving prognosis and the quality of life of patients undergoing cancer treatment. Studies have shown that physical exercise has positive effects on quality of life, autonomic function, cardiopulmonary function, strength, and functional capacity during the phases of anticancer therapy.
Given this scenario, this study is justified by the emerging need for knowledge about the benefits of physical training on cardiovascular capacity, contributing to the elucidation of clinical practice, effective decision-making, and better management of this population.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: ANDREA DIAS REIS A Teacher, PhD
- Numéro de téléphone: +5598987220570
- E-mail: andrea.dr@ufma.br
Sauvegarde des contacts de l'étude
- Nom: Abia Sousa studanty, Master's student
- Numéro de téléphone: +5598984666714
- E-mail: abiiasf@hotmail.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Patients with a confirmed diagnosis of cancer who are undergoing chemotherapy treatment with anthracyclines;
- No physical exercise intervention for the past 3 months;
- Patients in the early or intermediate stages of cancer treatment;
- Adult patients (e.g., 18 to 59 years old) to avoid extreme variations in response to physical exercise;
- Clinically stable patients, without absolute contraindications to physical exercise (e.g., decompensated heart failure, severe arrhythmias);
- Patients able to participate in a supervised physical exercise program during the study period
Exclusion Criteria:
- Patients with severe pre-existing cardiac conditions (e.g., advanced cardiomyopathy, unstable angina) that prevent safe exercise practice;
- Patients with physical (e.g., inability to walk) or cognitive limitations that prevent participation in the physical exercise program;
- Patients undergoing treatments that may interfere with the results (e.g., recent thoracic radiotherapy, use of cardiotoxic agents unrelated to the study);
- Patients who already engage in regular and intense physical exercise, as this could interfere with the effects of the intervention.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Experimental group: will undergo routine monitoring and evaluation, without exercise intervention.
Patients who will not participate in physical exercise programs, but will be monitored under the same clinical and monitoring conditions.
|
|
|
Expérimental: physical training
patients undergoing chemotherapy treatment who will perform physical exercise.
|
The concurrent physical training program will last 12 weeks and will consist of aerobic and resistance exercises.The physical exercises for aerobic training will consist of walking and/or cycling on a stationary bike, performed 3 times a week with progressive intensity.Strength training exercises for upper (UL) and lower (LL) limbs will be performed using dumbbells, ankle weights, resistance bands, and body weight for patients undergoing chemotherapy.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cardiotoxicity
Délai: From registration to the end of treatment in 12 weeks
|
The biomarkers used for cardiovascular assessment of cancer patients are: ultrasensitive troponin I or T (marker of myocardial injury).
|
From registration to the end of treatment in 12 weeks
|
|
Heart rate variability
Délai: From registration to the end of treatment in 12 weeks
|
Heart rate variability (HRV) will be measured using a Vantage V3 Polar® heart rate monitor that measures the electrical activity of the heart.
|
From registration to the end of treatment in 12 weeks
|
|
Cardiovascular risk in cancer patients.
Délai: From registration to the end of treatment in 12 weeks
|
Cardiovascular risk will be assessed using the Framingham Scale, which measures the risk of cardiovascular disease in individuals through blood pressure, lipid profile (LDL and HDL), smoking, and diabetes, based on this data, which will be collected from patients' medical records.
|
From registration to the end of treatment in 12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fatigue
Délai: From registration to the end of treatment in 12 weeks
|
Fatigue is a relevant symptom for cancer patients, with a greater impact than in the general population.
It is a symptom described at all stages of the oncology patient's journey, presenting as physical, emotional, or cognitive exhaustion or weakness, which can interfere with daily function and chemotherapy treatment.
|
From registration to the end of treatment in 12 weeks
|
|
pain assessment
Délai: From registration to the end of treatment in 12 weeks
|
Pain assessment will be measured using the Brief Pain Inventory (BPI), a 10-point pain intensity scale. Pain is a primary symptom among cancer patients and cancer survivors. Integrative interventions, such as acupuncture, massage, and music therapy, are effective non-pharmacological approaches for oncological pain with low cost and minimal adverse events |
From registration to the end of treatment in 12 weeks
|
|
Quality of life Global
Délai: From registration to the end of treatment in 12 weeks
|
The instrument used to assess Quality of life global for cancer will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-BR).
The higher scores mean a worse quality of life and lower scores mean a better quality of life.
|
From registration to the end of treatment in 12 weeks
|
|
Body Composition
Délai: From registration to the end of treatment in 12 weeks
|
Body composition will be assessed using bioimpedance.
Cancer leads to metabolic changes that contribute to depletion of nutritional status, resulting in alterations in body composition.
|
From registration to the end of treatment in 12 weeks
|
|
functional capacity
Délai: From registration to the end of treatment in 12 weeks
|
Functional capacity will be assessed by the 6-minute walk test (6MWT) performed in a 10m corridor.
The 6MWT test will measure the total distance covered (meter).
The greater the distance, the better the functional capacity.
|
From registration to the end of treatment in 12 weeks
|
|
adherence to physical exercise
Délai: From registration to the end of treatment in 12 weeks
|
Adherence will be determined through the patients' weekly attendance, and will be monitored by the researcher.
|
From registration to the end of treatment in 12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Manifestations neurologiques
- Conditions pathologiques, signes et symptômes
- Comportement
- Signes et symptômes
- La douleur
- Activité motrice
- Activité motrice
- Mouvement
- Phénomènes physiologiques musculo-squelettiques
- Phénomènes physiologiques musculo-squelettiques et neuronaux
- Exercice
- Conditionnement physique, humain
Autres numéros d'identification d'étude
- 88362125200005087
- CAAE:88362125200005087 (Autre identifiant: Funded by the researcher)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .